Harmony Biosciences price target lowered to $60 from $70 at Mizuho

Mizuho lowered the firm’s price target on Harmony Biosciences to $60 from $70 and keeps a Buy rating on the shares. The company’s Q4 results yesterday generally missed Wakix expectations, the analyst tells investors in a research note. The firm left the earnings call "somewhat less than satisfied," primarily around Harmony’s decision not to provide 2023 financial guidance. However, it sees an attractive risk/reward at current share levels.